# Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease

Study · id `cardio:ct-nct07180745` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07180745](<https://clinicaltrials.gov/study/NCT07180745>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07180745

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT07180745. Randomized; no masking; primary purpose treatment. Start 2025-11-01 (anticipated); primary completion 2026-02-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT07180745, source copy `cardio:ctgov-nct07180745-2025-09-18`, retrieved 2026-10-31)
- Planned start: 2025-11-01 (anticipated) (ClinicalTrials.gov record NCT07180745, source copy `cardio:ctgov-nct07180745-2025-09-18`, retrieved 2026-10-31)
- Primary completion: 2026-02-01 (anticipated) (ClinicalTrials.gov record NCT07180745, source copy `cardio:ctgov-nct07180745-2025-09-18`, retrieved 2026-10-31)
- Completion: 2026-03-01 (anticipated) (ClinicalTrials.gov record NCT07180745, source copy `cardio:ctgov-nct07180745-2025-09-18`, retrieved 2026-10-31)
- Countries: Egypt (ClinicalTrials.gov record NCT07180745, source copy `cardio:ctgov-nct07180745-2025-09-18`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07180745-2025-09-18`, retrieved 2026-10-31)

## The registry's words

- Brief title: Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease
- Condition: Non-alcoholic Fatty Liver Disease NAFLD
- Condition: Non-alcoholic Steatohepatitis NASH
- Intervention (Drug): Pioglitazone (PIO)
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Statin (Atorvastatin)
- Intervention (Drug): Empagliflozin plus Statin (Atorvastatin)
- Intervention (Drug): Pioglitazone plus Atorvastatin
- Lead sponsor: Badr University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Fatty liver disease (NAFLD / MASLD) (`cardio:nafld`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)

## Provenance

Content hash: 2056aa212daba53230a9e33a7c108486ffb886d5c453b43b105dc96972470dad
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
